Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

被引：3

作者：

Yeung, David T. ^{[1
,2
]}

Mauro, Michael J. ^{[3
]}

机构：

[1] SA Pathol, Dept Haematol & Mol Pathol, Adelaide, SA, Australia

[2] Univ Adelaide, Sch Med, Discipline Med, Adelaide, SA, Australia

[3] Mem Sloan Kettering Canc Ctr, Myeloproliferat Neoplasms Program, New York, NY 10065 USA

来源：

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2014年

基金：

英国医学研究理事会;

关键词：

BCR-ABL1 TRANSCRIPT LEVELS; FOLLOW-UP; IMATINIB; CML; PREDICT; DISCONTINUATION; RECOMMENDATIONS; DASATINIB; NILOTINIB; SURVIVAL;

D O I：

10.1182/asheducation-2014.1.240

中图分类号：

G40 [教育学];

学科分类号：

040101 ; 120403 ;

摘要：

A 55-year-old man presented with splenomegaly (10 cm below left costal margin) and leucocytosis (145 x 10(9)/L). Differential showed neutrophilia with increased basophils (2%), eosinophils (1.5%), and left shift including myeloblasts (3%). A diagnosis of chronic myeloid leukemia in chronic phase was established after marrow cytogenetics demonstrated the Philadelphia chromosome. Molecular studies showed a BCR-ABL1 qPCR result of 65% on the International Scale. Imatinib therapy at 400 mg daily was initiated due to patient preference, with achievement of complete hematological response after 4 weeks of therapy. BCR-ABL1 at 1 and 3 months after starting therapy was 37% and 13%, respectively (all reported on International Scale). Is this considered an adequate molecular response?

引用

页码：240 / 243

页数：4

共 50 条

[21] Higher Red Blood Cell Distribution Width Is an Adverse Prognostic Factor in Chronic-phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors [J].

Iriyama, Noriyoshi ;

Hatta, Yoshihiro ;

Kobayashi, Sumiko ;

Uchino, Yoshihito ;

Miura, Katsuhiro ;

Kurita, Daisuke ;

Kodaira, Hitomi ;

Takahashi, Hiromichi ;

Iizuka, Yoshikazu ;

Inoue, Mitsuru ;

Takei, Masami .

ANTICANCER RESEARCH, 2015, 35 (10) :5473-5478

[22] Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy [J].

Turkina, A. G. ;

Chelysheva, E. Yu. ;

Shuvaev, V. A. ;

Gusarova, G. A. ;

Bykova, A. V. ;

Shukhov, O. A. ;

Petrova, A. N. ;

Vakhrusheva, M. V. ;

Goryacheva, S. R. ;

Kolosova, L. Yu. ;

Krasikova, P. S. ;

Fominykh, M. S. ;

Martynkevich, I. S. ;

Abdullaev, A. O. ;

Sudarikov, A. B. ;

Savchenko, V. G. .

TERAPEVTICHESKII ARKHIV, 2017, 89 (12) :86-96

[23] Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors [J].

Sasaki, Koji ;

Kantarjian, Hagop M. ;

O'Brien, Susan ;

Ravandi, Farhad ;

Konopleva, Marina ;

Borthakur, Gautam ;

Garcia-Manero, Guillermo ;

Wierda, William G. ;

Daver, Naval ;

Ferrajoli, Alessandra ;

Takahashi, Koichi ;

Jain, Preetesh ;

Rios, Mary Beth ;

Pierce, Sherry A. ;

Jabbour, Elias J. ;

Cortes, Jorge E. .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (05) :545-552

[24] Late Responses in Patients With Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors [J].

Shaya, Justin ;

Pettit, Kristen ;

Kandarpa, Malathi ;

Bixby, Dale ;

Mercer, Jessica ;

Talpaz, Moshe .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (01) :17-23

[25] Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors [J].

Yilmaz, Musa ;

Lahoti, Amit ;

O'Brien, Susan ;

Nogueras-Gonzalez, Graciela M. ;

Burger, Jan ;

Ferrajoli, Alessandra ;

Borthakur, Gautam ;

Ravandi, Farhad ;

Pierce, Sherry ;

Jabbour, Elias ;

Kantarjian, Hagop ;

Cortes, Jorge E. .

CANCER, 2015, 121 (21) :3894-3904

[26] Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia [J].

La Rosee, Paul ;

Hochhaus, Andreas .

CURRENT OPINION IN HEMATOLOGY, 2010, 17 (02) :91-96

[27] Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors [J].

Kong, Jee Hyun ;

Winton, Elliott F. ;

Heffner, Leonard T. ;

Gaddh, Manila ;

Hill, Brittany ;

Neely, Jessica ;

Hatcher, Angela ;

Joseph, Meena ;

Arellano, Martha ;

El-Rassi, Fuad ;

Kim, Audrey ;

Khoury, Jean Hanna ;

Kota, Vamsi K. .

JOURNAL OF CLINICAL MEDICINE, 2020, 9 (05)

[28] Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety [J].

Garcia-Gutierrez, Valentin ;

Carlos Hernandez-Boluda, Juan .

FRONTIERS IN ONCOLOGY, 2019, 9

[29] Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia [J].

Giles, F. J. ;

O'Dwyer, M. ;

Swords, R. .

LEUKEMIA, 2009, 23 (10) :1698-1707

[30] Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia [J].

F J Giles ;

M O'Dwyer ;

R Swords .

Leukemia, 2009, 23 :1698-1707

← 1 2 3 4 5 →